Telix Pharmaceuticals Limited (TLX)
(Real Time Quote from BATS)
$11.77 USD
-0.20 (-1.67%)
Updated Aug 7, 2025 03:54 PM ET
After-Market: $11.77 0.00 (0.00%) 4:14 PM ET
4-Sell of 5 4
D Value B Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TLX 11.77 -0.20(-1.67%)
Will TLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Other News for TLX
Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry
Telix H1 2025 Results: Investor Webcast Notification | TLX Stock News
Telix Pharmaceuticals Faces SEC Investigation: Shares Plummet | TLX stock news
12 Health Care Stocks Moving In Wednesday's Intraday Session
First Look: Abivax Soars, Apple and Google Face UK Probe